eFFECTOR Therapeutics

A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal.  The SPAC Deal: eFFECTOR Therapeutics will merge with Locust Walk Acquisition Corp (NASDAQ: LWAC) in a deal bringing a next generation oncology company public. The deal...